38 Funle Successfully Listed on Nasdaq Capital Market
Industry: Women’s Health Biotechnology
Listing Date: 2022/12, Nasdaq Capital Market, USA
Funding Amount: 60 million USD
Partners: Tiger International (Tiger Brokers)
Yangkang Asset, in partnership with strategic partner Tiger Brokers, successfully assisted 38 Funle (TENKU) in listing on the Nasdaq Capital Market in the United States, successfully raising 60 million USD, becoming a benchmark company for the Asian women’s health biotech sector entering the international market. 38 Funle focuses on developing reproductive health, hormone balance, and health supplements, dedicated to providing comprehensive women’s health solutions.
After listing, 38 Funle retained its original brand and operational team, and continues to drive new product development and global market expansion. In 2024, the company strategically partnered with a tumor subsidiary of Citius Pharmaceuticals and merged with TenX Keane Acquisition Corp. (NASDAQ: TENKU), further forming Citius Oncology, Inc. (NASDAQ: CTOR). This transaction not only brought new medical technologies and market channels to the company but also demonstrated the team’s strategic capacity for diversified development and international cooperation.